1) Thompson GR, Blom DJ, Marais AD, et al:Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J 2018;39(14):1162-8 2) Stein EA, Dann EJ, Wiegman A, et al:Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations. J Am Coll Cardiol 2017;70(9):1162-70 3) Bláha V, Bláha M, Lánská M, et al:Lipoprotein apheresis in the treatment of dyslipidaemia-the Czech Republic experience. Physiol Res 2017;66(Supp 1):S91-100 4) Bruckert E, Kalmykova O, Bittar R, et al:Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France. Atherosclerosis 2017;257:130-7 5) Harada-Shiba M, Ikewaki K, Nohara A, et al:Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb 2017;24(4):402-11 6) Wang A, Richhariya A, Gandra SR, et al:Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J Am Heart Assoc 2016;5(7):pii:e003294 7) Coker M, Ucar SK, Simsek DG, et al:Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia. Ther Apher Dial 2009;13(2):121-8 8) Hudgins LC, Kleinman B, Scheuer A, et al:Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 2008;102(9):1199-204